Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
  • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
  • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
  • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
  • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
  • C07D239/56—One oxygen atom and one sulfur atom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
  • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
  • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
  • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
  • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
  • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/16—Amides, e.g. hydroxamic acids
  • A61K31/18—Sulfonamides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
  • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
  • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
  • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
  • C07D239/32—One oxygen, sulfur or nitrogen atom
  • C07D239/34—One oxygen atom

Definitions

• the present invention relates to a process for manufacturing the pyrimidine sulfamide derivatives of formula I
• R represents H, (Ci-C6)alkyl or benzyl.
• the compounds of formula I are endothelin receptor antagonists which have been first disclosed in WO 02/053557.
• macitentan compound of formula I wherein R is w-propyl; chemical names: N-[5-(4-bromophenyl)-6-[2-[(5-bromo- 2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl] -N'-propylsulfamide or N-[5-(4-bromophenyl)- 6- ⁇ 2-[(5-bromopyrimidin-2-yl)oxy]ethoxy ⁇ pyrimidin-4-yl]-N'-propylsulfuric diamide) is an endothelin receptor antagonist that is notably approved by the US Food and Drug Administration and the European Commission for the treatment of pulmonary arterial hypertension.
• the last step of one of the potential preparation routes described in WO 02/053557 called "Possibility A" and "Possibility B" can
• G 1 represents a reactive residue, and preferentially a chloro atom.
• G2 represents a reactive group such as a halogen atom (preferably a chlorine atom) and PG represents a protecting group such as a benzyl group or a 4-methoxy- or a 2,4-dimethoxybenzyl group.
• the compound of formula Io can be reacted with ethylene glycol in the presence of a base, in the presence or absence of an additional solvent and preferably at elevated temperatures.
• the resulting intermediate can then be reacted with 5-bromo-2-chloropyrimidine or an equivalent reactive entity in the presence of a strong base in a solvent such as THF, DMF, dioxane, etc. or mixtures thereof.
• the protecting group PG can then be removed by standard methods to yield the compound of formula I wherein R is H.
• reaction of the compound of formula I- 1 wherein X is chlorine with standard fluorinating agents such as KF or NaF did not yield the fluorinated intermediate with sufficient purity and yield.
• reaction of the compound of formula 1-1 wherein X is chlorine with sulfamide did not occur at 70°C in DMSO.
• a significant advantage of this alternative route is that it allows the use in the last step of a pyrimidine derivative already possessing a functionalised side chain at position 6 (i.e. the 2-(5-bromo-pyrimidin-2-yloxy)-ethoxy side chain), which avoids the use of an excess of ethylene glycol (required at some point to obtain the 2-(5-bromo-pyrimidin-2-yloxy)- ethoxy side chain - see e.g. WO 02/053557 or Bolli et al, J. Med. Chem. (2012), 55, 7849-7861) in a late stage of the manufacturing process.
• this route allows to use a single intermediate for preparing in a single step any compound of formula I wherein R represents H, (Ci-C6)alkyl or benzyl.
• the invention firstly relates to a process for manufacturing the compound of formula I
• R is H, (Ci-C6)alkyl or benzyl, or a salt thereof, said process comprising the reaction of the compound of formula 1-1
• X is bromine, chlorine or fluorine (and in particular chlorine or fluorine), with the compound of formula 1-2
• R is H, (Ci-C6)alkyl or benzyl, or a salt of said compound of formula 1-2, said reaction being performed in the presence of a base in a polar aprotic organic solvent or a polar mixture of aprotic organic solvents, and, when X is bromine or chlorine, in the presence of terra- w -butyl ammonium fluoride hydrate or cesium fluoride.
• the base used in the process according to embodiment 1) will be selected from the group consisting of NaOH, KOH, l,8-diazabicyclo[5.4.0]undec-7-ene, triethylamine, potassium tert-butylate, a 2 C03, K2CO 3 and CS2CO 3 (and notably from the group consisting of NaOH, KOH, l,8-diazabicyclo[5.4.0]undec-7-ene, triethylamine, potassium tert-butylate, a 2 C03 and K 2 CO 3 ).
• the base used in the process according to embodiment 1) will be K 2 CO 3 .
• reaction of the compound of formula I- 1 with the compound of formula 1-2 in the process according to one of embodiments 1) to 3) will be performed at a temperature from 20 to 140°C.
• reaction of the compound of formula I- 1 with the compound of formula 1-2 in the process according to one of embodiments 1) to 3) will be performed at a temperature from 60 to 80°C.
• reaction of the compound of formula I- 1 with the compound of formula 1-2 in the process according to one of embodiments 1) to 5) will be such that 0.9 to 4 equivalents (and in particular 0.9 to 1.5 equivalents) of compound of formula 1-2 are used per equivalent of compound of formula 1-1.
• reaction of the compound of formula I- 1 with the compound of formula 1-2 in the process according to one of embodiments 1) to 5) will be such that 1 to 3 equivalents (for example 1 to 1.5 equivalents and notably 1 to 1.2 equivalents) of compound of formula 1-2 are used per equivalent of compound of formula I- 1.
• reaction of the compound of formula I- 1 wherein X is chlorine with the compound of formula 1-2 in the process according to one of embodiments 1) to 7) will preferably be such that 1.1 to 10 equivalents of tetra-w-butyl ammonium fluoride hydrate or cesium fluoride are used per equivalent of compound of formula 1-1.
• reaction of the compound of formula 1-1 wherein X is chlorine with the compound of formula 1-2 in the process according to one of embodiments 1) to 7) will be such that 2 to 4 equivalents of tetra-w-butyl ammonium fluoride hydrate or cesium fluoride are used per equivalent of compound of formula 1-1.
• reaction of the compound of formula I- 1 with the compound of formula 1-2 in the process according to one of embodiments 1) to 9) will be such that 1.5 to 10 equivalents (and notably 1.5 to 5 equivalents) of base are used per equivalent of compound of formula I- 1.
• reaction of the compound of formula 1-1 with the compound of formula 1-2 in the process according to one of embodiments 1) to 9) will be such that 2 to 7 equivalents (and notably 2 to 4 equivalents) of K2CO 3 are used per equivalent of compound of formula I- 1.
• the reaction of the compound of formula I- 1 with the compound of formula 1-2 in the process according to one of embodiments 1) to 1 1) will be such that the polar aprotic organic solvent or polar mixture of aprotic organic solvents is selected from the group consisting of MeCN, chlorobenzene, iPrOAc, THF, NMP, dioxane, DMAC, DME, DMF, DMSO, sulfolane and a mixture of two solvents, whereby the first of these two solvents is selected from the group consisting of toluene and DCM and the second of these two solvents is selected from the group consisting of MeCN, chlorobenzene, iPrOAc, THF, NMP, dioxane, DMAC, DME, DMF, DMSO, sulfolane, and a mixture of toluene, DCM and a third solvent selected from the group consisting of MeCN, chlorobenzene,
• reaction of the compound of formula 1-1 with the compound of formula 1-2 in the process according to embodiment 12) will be performed using dimethylsulfoxide as solvent.
• the process of embodiments 1) to 14) will be performed in the presence of tetra-w-butyl ammonium fluoride hydrate.
• the process of embodiments 1) to 15) will be such X is chlorine and the reaction of the compound of formula I- 1 with the compound of formula 1-2 is performed in the presence tetra-w-butyl ammonium fluoride hydrate and using dimethylsulfoxide as solvent.
• the process of embodiments 1) to 14) will preferably be performed in the presence of cesium fluoride.
• the process of embodiment 16) will be such that 1.1 to 4 equivalents (and notably 1.1 to 1.5 equivalents or 1.1 to 1.3 equivalents) of cesium fluoride are used per equivalent of compound of formula I- 1.
• the compound of formula I or its salt will be such that R is H. 21) According to another variant of the process of embodiments 1) to 19), the compound of formula I or its salt will be such that R is (C 1 -Ce)alkyl.
• the compound of formula I or its salt will be such that R is w-propyl.
• the compound of formula I or its salt will be such that R is benzyl.
• the invention moreover relates to new synthetic intermediates useful in the preparation of the pyrimidine sulfamide derivatives of formula I, namely the compounds of formula I- 1
• the compound of formula I-l or its salt will be such that X is chlorine.
• the compound of formula I-l or its salt will be such that X is fluorine.
• the invention further relates to the use of a compound of formula I-l according to one of embodiments 24) to 26), or a salt thereof, in a process for manufacturing the compound of formula I as defined in embodiment 1) or a salt thereof.
• the compound of formula I-l or its salt in the use of embodiment 27) will be such that X is chlorine.
• the compound of formula I-l or its salt in the use of embodiment 27) will be such that X is fluorine.
• the compound of formula I or its salt will be such that R is H.
• the compound of formula I or its salt will be such that R is (Ci-C6)alkyl.
• the compound of formula I or its salt will be such that R is w-propyl.
• the compound of formula I or its salt will be such that R is benzyl.
• the invention moreover relates to the use of a compound of formula 1-1 according to embodiment 25), or a salt thereof, in a process for manufacturing the compound of formula 1-1 as defined in embodiment 26) or a salt thereof.
• the use according to embodiment 34) will be such that the process for manufacturing the compound of formula I- 1 as defined in embodiment 26) will comprise the reaction of the compound of formula I- 1 according to embodiment 25), or of a salt thereof, with tetra-w-butyl ammonium fluoride hydrate.
• the reaction of the compound of formula I- 1 according to embodiment 25), or of a salt thereof, with tetra-M-butyl ammonium fluoride hydrate will be performed in the presence of a base.
• the use according to embodiment 36) will be such that the base is selected from the group consisting of NaOH, KOH, l,8-diazabicyclo[5.4.0]undec-7-ene, triethylamine, potassium tert-butylate, a 2 C0 3 , K2CO 3 and CS2CO 3 (and in particular such that the base is selected from the group consisting of NaOH, KOH, l,8-diazabicyclo[5.4.0]undec-7-ene, triethylamine, potassium tert-butylate, a 2 C0 3 and K 2 C0 3 ).
• reaction of the compound of formula I- 1 according to embodiment 25), or of a salt thereof, with tetra-M-butyl ammonium fluoride hydrate will be performed in the absence of a base.
• the invention furthermore relates to a use as defined in one of embodiments 34) to 39), whereby the compound of formula I- 1 thus obtained is then used for manufacturing a compound of formula I as defined in embodiment 1).
• embodiment 40) will be such that the manufacture of a compound of formula I as defined in embodiment 1) will be performed by the reaction of the compound of formula I- 1 thus obtained, or a salt therof, with a compound of formula 1-2 as defined in embodiment 2), or a salt thereof in the presence of a base in a polar aprotic organic solvent or a polar mixture of aprotic organic solvents.
• the base used in the process according to embodiment 41) will be selected from the group consisting of NaOH, KOH, l,8-diazabicyclo[5.4.0]undec-7-ene, triethylamine, potassium tert-butylate, CS2CO 3 , a 2 C0 3 and K2CO 3 .
• the base used in the process according to embodiment 41) will be K2CO 3 .
• the reaction of the compound of formula 1-1 with the compound of formula 1-2 will be such that the polar aprotic organic solvent or polar mixture of aprotic organic solvents is selected from the group consisting of MeCN, chlorobenzene, iPrOAc, THF, NMP, dioxane, DMAC, DME, DMF, DMSO, sulfolane and a mixture of two solvents, whereby the first of these two solvents is selected from the group consisting of toluene and DCM and the second of these two solvents is selected from the group consisting of MeCN, chlorobenzene, iPrOAc, THF, NMP, dioxane, DMAC, DME, DMF, DMSO, sulfolane, and a mixture of toluene, DCM and a third solvent selected from the group consisting of MeCN, chlorobenzene, iPrOAc, THF, NMP, dioxane, DMAC, DME, D
• reaction of the compound of formula I- 1 with the compound of formula 1-2 in the use according to embodiment 44) will be such that the polar aprotic organic solvent or polar mixture of aprotic organic solvents comprises dimethylsulfoxide.
• reaction of the compound of formula I- 1 with the compound of formula 1-2 in the use according to embodiment 44) will be performed using dimethylsulfoxide as solvent.
• use according to embodiment 34) will be such that the process for manufacturing the compound of formula I- 1 as defined in embodiment 26) will comprise the reaction of the compound of formula I- 1 according to embodiment 25), or of a salt thereof, with cesium fluoride in the presence of a base.
• the use according to embodiment 47) will be such that the base is selected from the group consisting of NaOH, KOH, l,8-diazabicyclo[5.4.0]undec-7-ene, triethylamine, potassium tert-butylate, a 2 C0 3 , K2CO 3 and CS2CO 3 .
• the reaction of the compound of formula 1-1 with the compound of formula 1-2 will be such that the polar aprotic organic solvent or polar mixture of aprotic organic solvents is selected from the group consisting of MeCN, chlorobenzene, iPrOAc, THF, NMP, dioxane, DMAC, DME, DMF, DMSO, sulfolane and a mixture of two solvents, whereby the first of these two solvents is selected from the group consisting of toluene and DCM and the second of these two solvents is selected from the group consisting of MeCN, chlorobenzene, iPrOAc, THF, NMP, dioxane, DMAC, DME, DMF, DMSO, sulfolane, and a mixture of toluene, DCM and a third solvent selected from the group consisting of MeCN, chlorobenzene, iPrOAc, THF, NMP, dioxane, DMAC, DME, D
• reaction of the compound of formula I- 1 with the compound of formula 1-2 in the use according to embodiment 50) will be such that the polar aprotic organic solvent or polar mixture of aprotic organic solvents comprises dimethylsulfoxide.
• reaction of the compound of formula I- 1 with the compound of formula 1-2 in the use according to embodiment 50) will be performed using dimethylsulfoxide as solvent.
• This invention moreover relates to a process for manufacturing the compound of formula I
• R is H, (Ci-C6)alkyl or benzyl, or for manufacturing a salt thereof, said process comprising the reaction of the compound of formula I-l, said process comprising the following steps:
• R is H, (Ci-C6)alkyl or benzyl, or a salt thereof, in the presence of a base in a polar aprotic organic solvent or a polar mixture of aprotic organic solvents, to yield said compound of formula I or a salt thereof.
• step a) of the manufacturing process of embodiment 53) will be performed by reacting the compound of formula I-lci with cesium fluoride.
• the base used in step a) of the manufacturing process of embodiment 53) or 54) will be selected from the group consisting of NaOH, KOH, l,8-diazabicyclo[5.4.0]undec-7-ene, triethylamine, potassium tert-butylate, a 2 C03, K 2 C0 3 and Cs 2 C0 3 .
• the base used in step a) of the manufacturing process of embodiment 53) or 54) will be K2CO 3 .
• the base used in step b) of the manufacturing process of one of embodiments 53) to 56) will be selected from the group consisting of NaOH, KOH, l,8-diazabicyclo[5.4.0]undec-7-ene, triethylamine, potassium tert-butylate, a 2 C03, K 2 C0 3 and Cs 2 C0 3 .
• the base used in step b) of the manufacturing process of one of embodiments 53) to 56) will be K 2 C0 3 .
• K 2 C03 will be used as base in both steps a) and b) of the manufacturing process of embodiment 53) or 54).
• each of the polar aprotic organic solvent or polar mixture of aprotic organic solvents used in step a) and step b) will be independently selected from the group consisting of MeCN, chlorobenzene, iPrOAc, THF, NMP, dioxane, DMAC, DME, DMF, DMSO, sulfolane and a mixture of two solvents, whereby the first of these two solvents is selected from the group consisting of toluene and DCM and the second of these two solvents is selected from the group consisting of MeCN, chlorobenzene, iPrOAc, THF, NMP, dioxane, DMAC, DME, DMF, DMSO, sulfolane, and a mixture of toluene, DCM and a third solvent selected from the group consisting of MeCN, chlorobenzene, iPrOAc, THF
• each of the polar aprotic organic solvents or polar mixtures of aprotic organic solvents used in step a) and step b) will comprise dimethylsulfoxide.
• step a) and step b) of the process according to embodiment 60) will each be performed using dimethylsulfoxide as solvent.
• step a) of the manufacturing process will be performed by reacting the compound of formula I- 1 cl with cesium fluoride, and
• the base will independently be selected from the group consisting of NaOH, KOH, l,8-diazabicyclo[5.4.0]undec-7-ene, triethylamine, potassium tert-butylate, Na 2 C0 3 , K 2 C0 3 and Cs 2 C0 3 .
• the base will be CS2CO 3 in step a) of the manufacturing process of embodiment 63) or 64).
• the manufacturing process according to one of embodiments 53) to 65) will be such that R is w-propyl.
• the manufacturing process according to one of embodiments 53) to 65) will be such that R is H.
• This invention thus notably relates to the manufacturing processes, the compounds and uses as defined in one of embodiments 1), 24), 27), 34) and 53) or to these manufacturing processes, compounds and uses further limited under consideration of their respective dependencies by the characteristics of any one of embodiments 2) to 23), 25) and 26), 28) to 33), 35) to 39) and 54) to 67).
• the following manufacturing process, compound and use embodiments are thus possible and intended and herewith specifically disclosed in individualized form:
• 5-bromo-2-chloropyrimidine (compound IA) can be reacted (Scheme 1) with ethylene glycol in the presence of a base (e.g. tBuOK or DBU), affording 2-((5-bromopyrimidin- 2-yl)oxy)ethanol (compound 3 ⁇ 4).
• a base e.g. tBuOK or DBU
• Another method for obtaining the compound 3 ⁇ 4 would be to perform the reaction of 5-bromo-2-chloropyrimidine with 2-(tert-butoxy)ethanol in the presence of a base such as tBuOK and then the removal of the tert-butyl protecting group either by using cone. aq. HCl or by using formic acid followed by aq.
• the compound of formula I- 1 wherein X is F can be reacted with TBAF hydrate in the presence or the absence of a base in a polar aprotic solvent.
• the compound of formula Ic wherein X is Br or CI can be prepared by methods similar either to those described in Bolli et al, J. Med. Chem. (2012), 55, 7849-7861 or to those described in WO 2010/091824.
• the compound of formula 1-2 is either commercial (when R is H) or can be prepared by methods similar to those described in Bolli et al, J. Med. Chem. (2012), 55, 7849-7861 for obtaining the compound of formula 1-2 wherein R is w-propyl (when R is (Ci-C6)alkyl or benzyl).
• the compound of formula I- 1 wherein X is Br or CI can notably be used either for obtaining directly the compounds of formula I (see for example embodiment 1) above) or for obtaining the compound of formula I- 1 wherein X is F (by reaction with TBAF in the presence or the absence of a base).
• the compound of formula I- 1 wherein X is F can notably be used for obtaining the compounds of formula I (see for example embodiment 1) above).
• alkyl refers to a straight or branched chain alkyl group containing from one to six carbon atoms.
• (Ci-C x )alkyl (x being an integer) refers to a straight or branched chain alkyl group containing 1 to x carbon atoms. For example, a
• (Ci-C6)alkyl group contains from one to six carbon atoms.
• Representative examples of alkyl groups include methyl, ethyl, w-propyl, z ' sopropyl, w-butyl, z ' sobutyl, sec-butyl and tert-butyl.
• halogen refers to fluorine, chlorine, bromine or iodine, and preferably to fluorine or chlorine.
• polar aprotic solvent refers to a solvent which does not have an acidic hydrogen and has an electric dipole moment of at least 1.5 Debye.
• Representative examples of polar aprotic solvents include MeCN, chlorobenzene, EA, iPrOAc, THF, NMP, dioxane, DMAC, DME, DMF, DMSO or sulfolane.
• polar mixture of aprotic solvents refers to a mixture of solvents which do not have an acidic hydrogen, whereby said mixture has an electric dipole moment of at least 1.5 Debye.
• mixtures of aprotic solvents include, but are not limited to: a mixture of two solvents, whereby the first of these solvents is selected from the group consisting of toluene and DCM and the second of these solvents is selected from the group consisting of MeCN, chlorobenzene, EA, iPrOAc, THF, NMP, dioxane, DMAC, DME, DMF, DMSO and sulfolane; or a mixture of toluene, DCM and a solvent selected from the group consisting of MeCN, chlorobenzene, EA, iPrOAc, THF, NMP, dioxane, DMAC, DME, DMF, DMSO and sulfolane.
• room temperature refers to a temperature of from 20 to 30°C, and preferably 25°C.
• Example 2 The compound of Example 1 (20.0 g; 41.1 mmol; 1.0 eq.) and cesium fluoride (7.5 g; 49.3 mmol; 1.2 eq.) were suspended in DMSO (200 mL). It was heated to 70-75°C over 4 h. The brown reaction mixture was cooled to 20-25°C. It was diluted with EA (140 mL), washed with water (140 mL), a 10% aq. citric acid solution (140 mL) and brine (140 mL). It was concentrated to dryness to afford the title compound as a crude yellow solid. This material was suspended in iPrOH (40 mL) and heated to reflux for 10 min.
• Example 1 The compound of Example 1 (5.0 g; 10.3 mmol; 1.0 eq.) and TBAF.3H 2 0 (5.4 g; 17.0 mmol; 1.7 eq.) were suspended in DMSO (50 mL). The mixture was stirred at
• Example 1 A reactor was charged with compound of Example 1 (600 g; 1.23 mol; 1.0 eq.), cesium fluoride (562 g; 3.69 mol; 3.0 eq.), DMSO (3 L) and toluene (1.2 L). The toluene was distilled off, and the remaining mixture was stirred at 70 °C for 2 h. After cooling to RT, EA (2.4 L) and water (2.4 L) were added. The layers were separated, and the org. layer was successively washed with 7.5% w/v CaC . solution (2.4 L), brine (2.4 L) and water (3 L).
• Example 3 preparation of ⁇ 5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)- ethoxy] -pyrimidin-4-yl ⁇ -sulf amide :
• Example 2 The compound of Example 1 (25 g; 51.4 mmol), sulfamide (5.4 g; 56.5 mmol; 1.1 eq.), TBAF.3H 2 0 (48.6 g, 154 mmol, 3 eq.) and potassium carbonate (21.3 g, 154 mmol, 3 eq.) were suspended in DMSO (250 mL) at 20-25°C. The mixture was heated to 70-75°C for 1 h. At this point, LC-MS indicated complete conversion. The reaction mixture was cooled to 10-15°C. Water (200 mL) and DCM (350 mL) were added (caution: exotherm). The layers were separated and the org.
• Example 2 The compound of Example 1 (10 g; 20.6 mmol), sulfamide (2.2 g; 56.5 mmol; 1.1 eq.), TBAF.3H 2 0 (16.2 g, 51.4 mmol, 2.5 eq.) and potassium carbonate (7.1 g; 51.4 mmol; 2.5 eq.) were suspended in DMSO (50 mL) at 20-25°C. The mixture was heated to 70-75°C for 1 h. At this point, LC-MS indicated complete conversion. The reaction mixture was cooled to 10-15°C. Water (100 mL) and DCM (100 mL) were added (caution: exotherm). The layers were separated and the org.
• Example 1 The compound of Example 1 (100 g; 206 mmol), sulfamide (21.7 g; 226 mmol; 1.1 eq.), TBAF.3H 2 0 (162 g; 514 mmol; 2.5 eq.) and potassium carbonate (71 g; 514 mmol; 2.5 eq.) were suspended in DMSO (500 mL) at 20-25°C. The mixture was heated to 70-75°C for 2 h. At this point, LC-MS indicated complete conversion. The reaction mixture was cooled to 10-15°C. Water (1 L) and EA (1 L) were added (caution: exotherm). The layers were separated and the org. phase was washed with brine (1 L).
• Example 2 The compound of Example 2 (2 g; 4.25 mmol), sulfamide (0.45 g; 4.68 mmol; 1.1 eq.) and potassium carbonate (1.5 g; 10.6 mmol; 2.5 eq.) were suspended in DMSO (10 mL). It was heated to 70 °C for 15 h. The mixture was cooled to 20-25°C. A 40% aq. solution of citric acid was added dropwise (20 mL), followed by DCM (20 mL). The layers were separated and the org. phase was washed with brine (20 mL) and water (10 rnL). The combined org. layers were concentrated under reduced pressure to a residual volume of approx. 20 mL.
• the combined filtrate was acidified with IM H 2 SO 4 (10 mL) to furnish a cloudy solution. Addition of water (50 mL) led to formation of a suspension. The solid was filtered, washed twice with water (2 x 100 mL) and dried to give the title compound as a white powder (8.6 g; 77% yield).
• the product had NMR data equivalent to those reported in the supporting information associated with Bolli et al, J. Med. Chem. (2012), 55, 7849-7861.
• Example 4 preparation of propyl-sulfamic acid ⁇ 5-(4-bromo-phenyl)-6-[2-(5-bromo- pyrimidin-2-yloxy)-ethoxy] -pyrimidine-4-yl ⁇ -amide (macitentan) :
• Example 1 The compound of Example 1 (10 g; 20.6 mmol), propylsulfamide (3.1 g; 22.6 mmol; 1.1 eq.; prepared as described in Bolli et al, J. Med. Chem. (2012), 55, 7849-7861), TBAF.3H 2 0 (19.5 g; 61.7 mmol; 3 eq.) and potassium carbonate (8.5 g; 61.7 mmol; 3 eq.) were suspended in DMSO (100 mL). The mixture was heated to 100°C for 1 h and then cooled to 20-25°C. Water (100 mL) and DCM (100 mL) were added. The org.
• Example 5 preparation of benzyl-sulfamic acid ⁇ 5-(4-bromo-phenyl)-6-[2-(5-bromo- pyrimidin-2-yloxy)-ethoxy]-pyrimidine-4-yl ⁇ -amide:

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Engineering & Computer Science (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Heart & Thoracic Surgery (AREA)
• Cardiology (AREA)
• Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
• Plural Heterocyclic Compounds (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Catalysts (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Agricultural Chemicals And Associated Chemicals (AREA)
• Compositions Of Macromolecular Compounds (AREA)

Priority Applications (26)

Applications Claiming Priority (2)

Publications (1)

Family

ID=50073084

Family Applications (1)

Country Status (28)

Cited By (6)

Families Citing this family (7)

Citations (3)

Family Cites Families (9)

• 2014
  • 2014-02-14 EP EP14155137.4A patent/EP2907811A1/en not_active Withdrawn
• 2015
  • 2015-02-13 SG SG10201701994RA patent/SG10201701994RA/en unknown
  • 2015-02-13 AU AU2015217000A patent/AU2015217000B2/en active Active
  • 2015-02-13 KR KR1020177006399A patent/KR102406358B1/ko active Active
  • 2015-02-13 TW TW106114126A patent/TWI666203B/zh not_active IP Right Cessation
  • 2015-02-13 HR HRP20201450TT patent/HRP20201450T1/hr unknown
  • 2015-02-13 CN CN201710130956.7A patent/CN107162988B/zh active Active
  • 2015-02-13 EA EA201790343A patent/EA032460B1/ru not_active IP Right Cessation
  • 2015-02-13 BR BR112016018581-1A patent/BR112016018581B1/pt active IP Right Grant
  • 2015-02-13 SI SI201531349T patent/SI3105220T1/sl unknown
  • 2015-02-13 EP EP15706185.4A patent/EP3105220B1/en active Active
  • 2015-02-13 DK DK15706185.4T patent/DK3105220T3/da active
  • 2015-02-13 WO PCT/EP2015/053047 patent/WO2015121397A1/en not_active Ceased
  • 2015-02-13 US US15/118,046 patent/US9938244B2/en active Active
  • 2015-02-13 HU HUE15706185A patent/HUE050974T2/hu unknown
  • 2015-02-13 EA EA201691618A patent/EA032933B1/ru not_active IP Right Cessation
  • 2015-02-13 KR KR1020167025089A patent/KR102261695B1/ko active Active
  • 2015-02-13 MX MX2017003134A patent/MX377801B/es unknown
  • 2015-02-13 JP JP2016551796A patent/JP6431922B2/ja active Active
  • 2015-02-13 EP EP17159638.0A patent/EP3214082B1/en active Active
  • 2015-02-13 CN CN201580008410.3A patent/CN105992762B/zh active Active
  • 2015-02-13 ES ES17159638T patent/ES2906458T3/es active Active
  • 2015-02-13 ES ES15706185T patent/ES2819504T3/es active Active
  • 2015-02-13 PT PT157061854T patent/PT3105220T/pt unknown
  • 2015-02-13 MX MX2016010486A patent/MX368014B/es active IP Right Grant
  • 2015-02-13 BR BR122017005939-4A patent/BR122017005939B1/pt active IP Right Grant
  • 2015-02-13 CA CA2937277A patent/CA2937277C/en active Active
  • 2015-02-13 LT LTEP15706185.4T patent/LT3105220T/lt unknown
  • 2015-02-13 NZ NZ724273A patent/NZ724273A/en unknown
  • 2015-02-13 PL PL15706185T patent/PL3105220T3/pl unknown
  • 2015-02-13 SG SG11201606667VA patent/SG11201606667VA/en unknown
  • 2015-02-13 TW TW104105167A patent/TWI663155B/zh active
  • 2015-02-13 AR ARP150100449A patent/AR099434A1/es active IP Right Grant
• 2016
  • 2016-08-09 SA SA516371640A patent/SA516371640B1/ar unknown
  • 2016-08-10 CL CL2016002008A patent/CL2016002008A1/es unknown
• 2017
  • 2017-03-03 AR ARP170100539A patent/AR107801A2/es unknown
  • 2017-03-03 CL CL2017000505A patent/CL2017000505A1/es unknown
  • 2017-03-09 JP JP2017044868A patent/JP6421209B2/ja active Active
  • 2017-03-13 IL IL251126A patent/IL251126A0/en active IP Right Grant
  • 2017-04-12 AU AU2017202446A patent/AU2017202446B2/en not_active Ceased
• 2018
  • 2018-02-27 HK HK18102771.1A patent/HK1243405A1/en unknown
• 2020
  • 2020-09-04 CY CY20201100833T patent/CY1123319T1/el unknown

Patent Citations (3)

Also Published As

Similar Documents

Legal Events